Carl Byrnes
Stock Analyst at Northland Capital Markets
(2.21)
# 2,715
Out of 4,944 analysts
23
Total ratings
46.67%
Success rate
8.94%
Average return
Main Sectors:
Stocks Rated by Carl Byrnes
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLFS BioLife Solutions | Maintains: Outperform | $28 → $31 | $24.02 | +29.06% | 2 | Jan 8, 2025 | |
| TLSI TriSalus Life Sciences | Initiates: Outperform | $13 | $3.65 | +242.47% | 1 | Oct 25, 2024 | |
| BWAY BrainsWay | Maintains: Outperform | $11 → $13 | $12.19 | +2.54% | 3 | Oct 3, 2024 | |
| MDAI Spectral AI | Initiates: Outperform | $6 | $2.23 | +169.06% | 1 | Aug 12, 2024 | |
| COCH Envoy Medical | Initiates: Outperform | n/a | $1.47 | - | 1 | Dec 21, 2023 | |
| AMRN Amarin Corporation | Maintains: Market Perform | $40 → $25 | $14.88 | +68.01% | 1 | Jul 19, 2023 | |
| CDIO Cardio Diagnostics Holdings | Initiates: Outperform | $240 | $3.66 | +6,457.38% | 1 | May 22, 2023 | |
| VTVT vTv Therapeutics | Maintains: Outperform | $60 → $80 | $14.49 | +452.10% | 4 | Aug 17, 2022 | |
| MDXG MiMedx Group | Initiates: Outperform | $23 | $7.23 | +218.12% | 3 | Jul 26, 2021 | |
| ESPR Esperion Therapeutics | Maintains: Market Perform | $30 → $24 | $1.79 | +1,240.78% | 4 | May 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $2,000 | $2.25 | +88,788.89% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.31 | - | 1 | Sep 27, 2017 |
BioLife Solutions
Jan 8, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $24.02
Upside: +29.06%
TriSalus Life Sciences
Oct 25, 2024
Initiates: Outperform
Price Target: $13
Current: $3.65
Upside: +242.47%
BrainsWay
Oct 3, 2024
Maintains: Outperform
Price Target: $11 → $13
Current: $12.19
Upside: +2.54%
Spectral AI
Aug 12, 2024
Initiates: Outperform
Price Target: $6
Current: $2.23
Upside: +169.06%
Envoy Medical
Dec 21, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.47
Upside: -
Amarin Corporation
Jul 19, 2023
Maintains: Market Perform
Price Target: $40 → $25
Current: $14.88
Upside: +68.01%
Cardio Diagnostics Holdings
May 22, 2023
Initiates: Outperform
Price Target: $240
Current: $3.66
Upside: +6,457.38%
vTv Therapeutics
Aug 17, 2022
Maintains: Outperform
Price Target: $60 → $80
Current: $14.49
Upside: +452.10%
MiMedx Group
Jul 26, 2021
Initiates: Outperform
Price Target: $23
Current: $7.23
Upside: +218.12%
Esperion Therapeutics
May 5, 2021
Maintains: Market Perform
Price Target: $30 → $24
Current: $1.79
Upside: +1,240.78%
Oct 22, 2018
Initiates: Outperform
Price Target: $2,000
Current: $2.25
Upside: +88,788.89%
Sep 27, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.31
Upside: -